# Bioequivalence of a Single Subcutaneous Dose of BEPO and REPO in Healthy Male Subjects

> **NCT02426151** · PHASE1 · COMPLETED · sponsor: **LG Life Sciences** · enrollment: 46 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BEPO-A
- **DRUG:** REPO-A

## Key facts

- **NCT ID:** NCT02426151
- **Lead sponsor:** LG Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2015-05
- **Final completion:** 2015-09
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2016-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02426151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02426151, "Bioequivalence of a Single Subcutaneous Dose of BEPO and REPO in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02426151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*